Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials

D’Haens, Geert; D R Higgins, Peter; Peyrin-Biroulet, Laurent; E Sands, Bruce; Lee, Scott; E Moses, Richard; Redondo, Isabel; Escobar, Rodrigo; Hunter Gibble, Theresa; Keohane, Anthony; Morris, Nathan; Zhang, Xin; Arora, Vipin; Kobayashi, Taku

doi:10.1093/ibd/izae004

Public

Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials

Shared by NobleBlocks on Jan 25, 2024 • 12:00 AM UTC

Authors:

Geert D’Haens

Peter D R Higgins

Laurent Peyrin-Biroulet

Abstract

Abstract Background Efficacy and safety of mirikizumab, a p19-targeted anti-interleukin-23 monoclonal antibody, for moderately to severely active ulcerative colitis was demonstrated previously. We evaluated clinical response, baseline characteristics, and clinical status in patients not responding b...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!